Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

126 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
NO signaling confers cytoprotectivity through the survivin network in ovarian carcinomas.
Engels K, Knauer SK, Loibl S, Fetz V, Harter P, Schweitzer A, Fisseler-Eckhoff A, Kommoss F, Hanker L, Nekljudova V, Hermanns I, Kleinert H, Mann W, du Bois A, Stauber RH. Engels K, et al. Among authors: nekljudova v. Cancer Res. 2008 Jul 1;68(13):5159-66. doi: 10.1158/0008-5472.CAN-08-0406. Cancer Res. 2008. PMID: 18593915
Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.
von Minckwitz G, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Kreienberg R, Solbach C, Gerber B, Jackisch C, Kunz G, Blohmer JU, Huober J, Hauschild M, Fehm T, Müller BM, Denkert C, Loibl S, Nekljudova V, Untch M; German Breast Group; Arbeitsgemeinschaft Gynäkologische Onkologie–Breast Study Groups. von Minckwitz G, et al. Among authors: nekljudova v. N Engl J Med. 2012 Jan 26;366(4):299-309. doi: 10.1056/NEJMoa1111065. N Engl J Med. 2012. PMID: 22276820 Free article. Clinical Trial.
What can be learned from trials running short of patients or events?
von Minckwitz G, Nekljudova V, Loibl S. von Minckwitz G, et al. Among authors: nekljudova v. J Clin Oncol. 2012 Mar 20;30(9):901-3. doi: 10.1200/JCO.2011.40.3022. Epub 2012 Feb 13. J Clin Oncol. 2012. PMID: 22331931 No abstract available.
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Konecny GE, Denkert C, Nekljudova V, Mehta K, Loibl S. von Minckwitz G, et al. Among authors: nekljudova v. J Clin Oncol. 2012 May 20;30(15):1796-804. doi: 10.1200/JCO.2011.38.8595. Epub 2012 Apr 16. J Clin Oncol. 2012. PMID: 22508812
RNA-based determination of ESR1 and HER2 expression and response to neoadjuvant chemotherapy.
Denkert C, Loibl S, Kronenwett R, Budczies J, von Törne C, Nekljudova V, Darb-Esfahani S, Solbach C, Sinn BV, Petry C, Müller BM, Hilfrich J, Altmann G, Staebler A, Roth C, Ataseven B, Kirchner T, Dietel M, Untch M, von Minckwitz G. Denkert C, et al. Among authors: nekljudova v. Ann Oncol. 2013 Mar;24(3):632-9. doi: 10.1093/annonc/mds339. Epub 2012 Nov 6. Ann Oncol. 2013. PMID: 23131391 Free article.
Predictive value of sphingosine kinase 1 expression in neoadjuvant treatment of breast cancer.
Ruckhäberle E, Karn T, Denkert C, Loibl S, Ataseven B, Reimer T, Becker S, Holtrich U, Rody A, Darb-Esfahani S, Nekljudova V, von Minckwitz G. Ruckhäberle E, et al. Among authors: nekljudova v. J Cancer Res Clin Oncol. 2013 Oct;139(10):1681-9. doi: 10.1007/s00432-013-1490-5. Epub 2013 Aug 18. J Cancer Res Clin Oncol. 2013. PMID: 23955546
Monounsaturated fatty acids in serum triacylglycerols are associated with response to neoadjuvant chemotherapy in breast cancer patients.
Hilvo M, Gade S, Hyötyläinen T, Nekljudova V, Seppänen-Laakso T, Sysi-Aho M, Untch M, Huober J, von Minckwitz G, Denkert C, Orešič M, Loibl S. Hilvo M, et al. Among authors: nekljudova v. Int J Cancer. 2014 Apr 1;134(7):1725-33. doi: 10.1002/ijc.28491. Epub 2013 Oct 8. Int J Cancer. 2014. PMID: 24114462 Free article.
Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial.
Issa-Nummer Y, Darb-Esfahani S, Loibl S, Kunz G, Nekljudova V, Schrader I, Sinn BV, Ulmer HU, Kronenwett R, Just M, Kühn T, Diebold K, Untch M, Holms F, Blohmer JU, Habeck JO, Dietel M, Overkamp F, Krabisch P, von Minckwitz G, Denkert C. Issa-Nummer Y, et al. Among authors: nekljudova v. PLoS One. 2013 Dec 2;8(12):e79775. doi: 10.1371/journal.pone.0079775. eCollection 2013. PLoS One. 2013. PMID: 24312450 Free PMC article. Clinical Trial.
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.
von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, Blohmer JU, Jackisch C, Paepke S, Gerber B, Zahm DM, Kümmel S, Eidtmann H, Klare P, Huober J, Costa S, Tesch H, Hanusch C, Hilfrich J, Khandan F, Fasching PA, Sinn BV, Engels K, Mehta K, Nekljudova V, Untch M. von Minckwitz G, et al. Among authors: nekljudova v. Lancet Oncol. 2014 Jun;15(7):747-56. doi: 10.1016/S1470-2045(14)70160-3. Epub 2014 Apr 30. Lancet Oncol. 2014. PMID: 24794243 Clinical Trial.
126 results